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Dear Editor,
Reciprocity of depressive and psychotic symptoms in patients with 
schizophrenia and major depression disorder (MDD), respectively, 
complicates differential psychiatric diagnosis. Notably, 60%-70% of 
schizophrenia patients experience moderate to severe depressive 
symptoms1-3. Indeed, schizophrenia and MDD have been proposed to 
be variants of the same disorder, namely major psychiatric disorder1. 
Notwithstanding, distinct functional brain characteristics of these 
two patient groups have been demonstrated2. Additionally, patients 
with schizophrenia and MDD have been reported to have reduced 
and increased corpus callosum (CC) sizes, respectively3-5. Thus, we 
have hypothesized that there may be a depressive-type schizophrenia. 
This study was approved by the ethical committee of The Tianjin 
Mental Health Center. All procedures performed in studies involving 
human participants were in accordance with the ethical standards 
of the institutional and/or national research committee and with the 
1964 Helsinki declaration and its later amendments or comparable 
ethical standards. Written informed consent was obtained from 
participants and their guardians.
We used magnetic resonance imaging (MRI) and tract-based 
spatial statistics (TBSS) to compare the CCs of first-episode drug-
naïve schizophrenia patients with (FE-SCZ-D) versus without 
(FE-SCZ-nD) depressive symptoms (N = 15/group), matched for 
demographics and symptom severity, and 20 healthy controls (HCs) 
who served as a reference group. None of the participants had a family 
history of mental illness. Their mean ages ± standard deviations (SDs) 
by group were: FE-SCZ-D, 24.5 ± 4.5 years; FE-SCZ-nD, 23.5 ± 2.5 
years; and HC, 24.5 ± 3.5 years (R = 0.557; p = 0.405). The gender 
ratios of the groups were (males/females): FE-SCZ-D, 8/7; FE-SCZ-
nD, 9/6; and HC, 7/8 (p = 0.265). The FE-SCZ-D and FE-SCZ-nD 
groups had mean (±SD) illness durations of 2.3 ± 1.2 months and 2.8 
± 1.4 months, respectively (R = 0.362; p = 0.265). The FE-SCZ-D and 
FE-SCZ-nD groups had mean (±SD) Positive and Negative Syndrome 
Scale scores of 80.0 ± 19.0 and 82.6 ± 17.7, respectively (R = 0.523; 
p = 0.799), and they had mean (±SD) Calgary Depression Scale for 
Schizophrenia scores of 15.5 ± 1.5 and 0.0 ± 0.0, respectively. This 
pilot study was completed from January 1st to December 31st of 2018. 
All participants volunteered and gave written informed consent; the 
Wenzhou Seventh People’s Hospital provided ethics approval. 
TBSS analysis of MRI data showed more pronounced CC 
reductions in the FE-SCZ-nD group than in the FE-SCZ-D group; 
both schizophrenic patient groups had reduced CCs relative to HCs 
(Figure 1). Hence, the presence of depressive symptoms seemed to 
Figure 1. TBSS-based comparison of MRI examinations of white matter 
structures, especially CC connections, between a HC reference group (A), 
FE-SCZ-D patients (B), and FE-SCZ-nD patients (C).
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counter, or perhaps be a protective factor against, CC reduction 
in patients with schizophrenia. These findings are consistent 
with our hypothesis that there may be a distinct depression-type 
schizophrenia.
Limitations of this study included a small sample size, all patients 
being inpatients (due to imperative auditory hallucinations) who 
refused antipsychotic treatment prior to hospitalization, participant 
loss (6 per patient group) due to MRI noncompliance, and limited-
resolution images. Larger-cohort and multi-center studies with more 
subtle neuroimaging are needed to clarify brain alterations related 
to psychosis and depressiveness.
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